Hematopoietic stem cell transplantation (HSCT) plays an important role in treating younger patients with acute myeloid leukemia (AML). Reduced-intensity conditioning regimens allow increased use of allogeneic HSCT for older patients. Current HSCT decisions in patients with AML are being made according to cytogenetic analysis results. A more comprehensive and detailed understanding of the genetic and epigenetic changes that are related to the pathogenesis of AML is required for better classification of risk and for improving approaches to therapy as they pertain to future HSCT decisions.
|Number of pages||10|
|Journal||[Rinshō ketsueki] The Japanese journal of clinical hematology|
|Publication status||Published - Oct 1 2015|
All Science Journal Classification (ASJC) codes